Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

Blood

Volumn 127, Issue 24, 2016, Pages 3004-3014

  He, Jie ^a   Abdel Wahab, Omar ^b   Nahas, Michelle K ^a   Wang, Kai ^a   Rampal, Raajit K ^b   Intlekofer, Andrew M ^b   Patel, Jay ^b   Krivstov, Andrei ^b   Frampton, Garrett M ^a   Young, Lauren E ^a   Zhong, Shan ^a   Bailey, Mark ^a   White, Jared R ^a   Roels, Steven ^a   Deffenbaugh, Jason ^a   Fichtenholtz, Alex ^a   Brennan, Timothy ^a   Rosenzweig, Mark ^a   Pelak, Kimberly ^a   Knapp, Kristina M ^b   Brennan, Kristina W ^a   Donahue, Amy L ^a   Young, Geneva ^a   Garcia, Lazaro ^a   Beckstrom, Selmira T ^a   Zhao, Mandy ^a   White, Emily ^a   Banning, Vera ^a   Buell, Jamie ^a   Iwanik, Kiel ^a   Ross, Jeffrey S ^a   Morosini, Deborah ^a   Younes, Anas ^b   Hanash, Alan M ^b   Paietta, Elisabeth ^c   Roberts, Kathryn ^d   Mullighan, Charles ^d   Dogan, Ahmet ^b   Armstrong, Scott A ^b   Mughal, Tariq ^a,e   Vergilio, Jo Anne ^a   Labrecque, Elaine ^a   Erlich, Rachel ^a   Vietz, Christine ^a   Yelensky, Roman ^a   Stephens, Philip J ^a   Miller, Vincent A ^a   Van Den Brink, Marcel R M ^b   Otto, Geoff A ^a   Lipson, Doron ^a   Levine, Ross L ^b   more..

^a FOUNDATION MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCND1 PROTEIN; GENOMIC DNA; GENOMIC RNA; MYC PROTEIN; PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; DNA; RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BONE MARROW; BURKITT LYMPHOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DETERMINATION; DNA SEQUENCE; EXON; FOLLICULAR LYMPHOMA; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE FUSION; GENE INSERTION; GENE REARRANGEMENT; GENETIC VARIABILITY; GRANULOCYTIC SARCOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INDEL MUTATION; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NEXT GENERATION SEQUENCING; NUCLEIC ACID BASE SUBSTITUTION; PLASMACYTOMA; PRIORITY JOURNAL; RNA ANALYSIS; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN LYMPHOMA; T CELL LYMPHOMA; CHROMOSOME ABERRATION; DNA FINGERPRINTING; DNA MUTATIONAL ANALYSIS; EVALUATION STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; GENOMICS; HEMATOLOGIC DISEASE; HIGH THROUGHPUT SEQUENCING; LABORATORY TECHNIQUE; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; SYSTEM ANALYSIS;

CHROMOSOME ABERRATIONS; CLINICAL LABORATORY TECHNIQUES; DNA FINGERPRINTING; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HEMATOLOGIC NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; POLYMORPHISM, GENETIC; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; SYSTEMS INTEGRATION;

EID: 84993661482     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-664649     Document Type: Article

References (30)

1. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
3. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
4. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268-274.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
6. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153-158.
7. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
8. Nucifora G, Birn DJ, Erickson P, et al. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood. 1993;81(4):883-888.
9. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 1995;92(11):4917-4921.
10. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.
11. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science. 1983;219(4587):963-967.
12. Byrd JC, Mrózek K, Dodge RK, et al; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
13. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
14. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56(6):1418-1425.
15. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14(5):796-804.
16. Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544-3546.
17. Bernicot I, Douet-Guilbert N, Le Bris MJ, et al. Characterization of IGH rearrangements in non-Hodgkin's B-cell lymphomas by fluorescence in situ hybridization. Anticancer Res. 2005;25(5):3179-3182.
18. Vincent-Fabert C, Fiancette R, Cogné M, Pinaud E, Denizot Y. The IgH 3′ regulatory region and its implication in lymphomagenesis. Eur J Immunol. 2010;40(12):3306-3311.
19. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene. 2003;22(20):3087-3091.
20. Wellmann S, Moderegger E, Zelmer A, et al. FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse. Leukemia. 2005;19(3):467-468.
21. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260-263.
22. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552-1559.
23. Fröhling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501-513.
24. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153-166.
25. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
26. Mullighan CG, Su X, Zhang J, et al; Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
27. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.
28. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-1214.
29. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107(1):252-257.
30. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484-1492.